CT-BOEHRINGER-INGELHEIM
Yale University, in partnership with Boehringer Ingelheim, today announced the launch of a Biomedical Data Science Fellowship program designed to attract and support some of the brightest and most innovative minds in data science from around the world.
Post-doctoral researchers awarded a three-year fellowship will have access to Yale’s robust computational resources, biomedical data repositories and faculty expertise. In addition, they will benefit from access to Boehringer Ingelheim’s corporate labs, scientists and executives. Applicants are invited to submit research proposals for consideration by June 15. If approved for a fellowship, they will be jointly mentored throughout the research process by industry experts and scientists from Boehringer Ingelheim — one of the world’s leading pharmaceutical companies — as well as Yale’s world-class researchers and scholars. Fellowship training begins Sept. 1.
“This collaboration with Boehringer Ingelheim creates a world-class data science fellowship program that will drive development of novel methods and tools to analyze and interpret the many large and complex biomedical datasets that have been created in recent years,” said Yale School of Public Health Professor of Biostatistics, Genetics, Statistics, and Data Science Hongyu Zhao, PhD, principal investigator for the project.
The program will be based at the Yale Center for Biomedical Data Science (CBDS) in New Haven, Connecticut. The center is an essential part of a growing data science hub at Yale University, which has identified integrated data science as one of its primary investment areas over the next decade. CBDS is located within Yale School of Medicine and currently supports more than 100 faculty members and researchers representing such disciplines as bioinformatics, modeling, statistics, computer science, artificial intelligence, mathematics, biology, precision medicine and public health.
“In partnering with a top-tier academic and research institution like Yale, we aim to recruit and train a new generation of highly skilled data scientists to help us accelerate development of novel treatments and therapies for human disease and improve health outcomes for our patients,” said Jan Nygaard Jensen, PhD, Global Head of Computational Biology and Digital Sciences at Boehringer Ingelheim.
The partnership reflects a mutual vision between Boehringer Ingelheim and Yale University. It is part of a comprehensive strategic program at Boehringer Ingelheim which will harness the power of data science to transform drug discovery and development. The aim is to catalyze the next breakthrough therapies that change lives by accelerating timelines, improving scientific and clinical success and further elevating patient centricity.
“Boehringer Ingelheim is pleased to build upon our successful relationships with Yale to foster the next generation of scientists and harness the power of data science to bring our vision of making new and better medicines for patients in need,” said Clive R. Wood, PhD, Senior Corporate Senior Vice President, Global Head, Discovery Research, Boehringer Ingelheim. “We believe our shared ambition and outlook will build a world-class data science community to attract outstanding researchers and work to achieve breakthroughs that patients need.”
Initially the program will award as many as three competitive fellowships per year, up to a total of nine over the first five years. In addition to receiving research funding and mentorship, program fellows will be invited to participate in campus and corporate visits, networking events and annual symposia.
A joint selection committee comprising representatives of Yale and Boehringer Ingelheim will set annual data-driven research themes for the program. These themes may include such topics as genomic analysis, biomarkers, data-driven therapeutic research, medical image informatics, precision medicine and translational medicine. The selection committee will consider proposed research projects’ alignment with prioritized themes in judging submissions and post-doctoral applicants.
Yale’s data science ecosystem is supported by a host of cutting-edge research institutions working collaboratively. In addition to CBDS, they include Yale’s Systems Biology Institute , Center for Mendelian Genomics , Center for RNA Science and Medicine , and Center for Medical Informatics . Yale’s biobanks and technology core include: the Yale BioBank GENERATIONS, VA Million Veteran Program , Center for Research Computing , Center for Genomic Health , and Center for Genomic Analysis , which houses the ninth largest genomic library in the world.
Xinxin (Katie) Zhu, MD, PhD, executive director of the Yale Center for Biomedical Data Science, said the fellowship program offers an exciting opportunity for the development of innovative data-driven approaches for different medical conditions that can be translated from the lab to the patient’s bedside. It is an especially opportune time, she said.
“The vast amount of biomedical data being generated today has created a tremendous need for highly skilled data scientists who can use this information to advance care,” said Zhu.
Specialists in biomedical data science and health informatics can identify statistical associations and patterns of disease. They also can develop complex machine learning models and simulations of molecular, cellular and organismic systems to increase the probability of clinical success through precision medicine and other methods.
“This helps clinicians and pharmaceutical companies such as Boehringer Ingelheim identify potential new pathways for treatment and eradication of disease,” Zhu said.
To apply for a Yale-Boehringer Ingelheim Biomedical Data Science Fellowship, please go to https://medicine.yale.edu/cbds/bdsfellowship .
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/collaboration-yale
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005445/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MultiBank Group Confirms $MBG Token TGE Set for July 22, 202512.7.2025 11:14:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250712404220/en/ MultiBank Group has officially announced that the Token Generation Event (TGE) for its highly anticipated $MBG Token will take place on July 22, 2025. This milestone will mark the full activation of the $MBG Token on the blockchain, enabling holders to view and manage their balances across supported platforms. Following the token minting, users will be able to trade $MBG via MultiBank.io, the Group’s regulated crypto exchange and Uniswap, the world’s leading decentralized platform. The $MBG Token has garnered global attention for its rare combination of real-world utility, institutional backing, and strong deflationary mechanics. It is underpinned by $29 billi
Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics11.7.2025 14:00:00 CEST | Press release
Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs). The pilot marks another step toward making PCTs more accessible, timely, and scalable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711152688/en/ As late-stage PCT clinical trials progress and therapy developers work to create the next generation of PCTs, the speed, reliability, scaling and cost of traditional production methods pose a major challenge. Specifically, the first step of DNA template production is hi
$MBG Token Pre-Sale Set for July 15 — Only 7 Million Tokens Available at $0.3511.7.2025 10:17:00 CEST | Press release
MultiBank Group, the world’s largest financial derivatives institution headquartered in Dubai, has confirmed that its highly anticipated $MBG Token pre-sale will go live on July 15, with demand expected to be intense. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711737311/en/ With only 7 million $MBG tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. With only 7 million tokens up for grabs at an exclusive entry price of $0.35, this is a rare opportunity to secure early access to what many are calling the year’s most powerful utility asset. Early participants can join simultaneously on MultiBank.io, the Group’s regulated crypto exchange, and Uniswap, the world’s leading decentralized platform. Supported by $29 billion in real assets and powered by over $35 billion in daily turnover, $MBG is engineered
Live Story Raises €2.7 Million to Revolutionize the Digital Experience11.7.2025 10:05:00 CEST | Press release
With a round led by Vertis, the next-generation CMS platform accelerates its focus onAI, performance, and European expansion. Target: surpass €10M in recurring revenueby 2027. Live Story, the tech company founded by Stefano Mocellini, has closed a €2.7 million seed round led by Vertis, one of Italy’s leading early-growth venture capital firms. The funding will support the company’s international expansion and technological development, with a clear goal: to exceed €10 million in annual recurringrevenue by 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250711335560/en/ “We invested in Live Story because it addresses one of the major inefficiencies in digital commerce: the slow and rigid management of visual and narrative content,” says Alessandro Pontari, Partner at Vertis SGR. “The platform helps brands drastically reduce their time-to-market through a visual CMS that integrates seamlessly with any tech stack. In a wor
With a Score of 84 out of 100, Sagemcom Is Awarded the EcoVadis Platinum Medal: a Prestigious Recognition of its CSR Commitment11.7.2025 09:00:00 CEST | Press release
Sagemcom Group is proud to announce that it has been awarded, for the third time, the Platinum Medal by EcoVadis, the highest distinction granted by the leading global platform for assessing Corporate Social Responsibility (CSR) performance. This medal places Sagemcom in the top 1% of companies evaluated worldwide, across all industries. With a score of 84 out of 100, Sagemcom reaffirms its position as a committed leader in ecological transition, business ethics, sustainable supply chain management, and social responsibility. “The EcoVadis Platinum Medal is more than just an award — it is the recognition of our collective efforts to embed sustainable development principles at the heart of our corporate strategy and culture,” says Sylvaine Couleur, Executive Vice President, CSR & Communication. “Achieving this level demonstrates that our commitments are tangible, impactful, and internationally recognized. This distinction strengthens our determination to further advance and expand our C
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom